BiotechTube

Amevive

Pre-clinicalWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Kidney Transplantation

Conditions

Kidney Transplantation

Trial Timeline

Oct 1, 2011 → Oct 1, 2014

NCT ID
NCT01433770

About Amevive

Amevive is a pre-clinical stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01433770. Target conditions include Kidney Transplantation.

What happened to similar drugs?

20 of 20 similar drugs in Kidney Transplantation were approved

Approved (20) Terminated (1) Active (0)
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅TacrolimusAstellas PharmaApproved
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
✅Tacrolimus granulesAstellas PharmaApproved
✅Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved
✅MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
✅Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01433770Pre-clinicalWithdrawn

Competing Products

20 competing products in Kidney Transplantation

See all competitors
ProductCompanyStageHype Score
Empagliflozin + Matching placeboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 2
35
SGLT2 inhibitorEli LillyPre-clinical
30
LY2623091 + EplerenoneEli LillyPhase 2
35
Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
39
TacrolimusAstellas PharmaApproved
35
RituximabAstellas PharmaPhase 2
35
Prograf + MR4Astellas PharmaPhase 3
40
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
43
Tacrolimus, modified releaseAstellas PharmaPhase 3
40
Tacrolimus granulesAstellas PharmaApproved
43
roxadustatAstellas PharmaPhase 3
40
Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved
43
ASP1128 + PlaceboAstellas PharmaPhase 2
35
FK506MR + Prograf + Mycophenolate Mofetil + Methylprednisolone + PrednisoloneAstellas PharmaPhase 3
40
MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
43
ASP1585Astellas PharmaPhase 3
40
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + CorticosteroidsAstellas PharmaPhase 2
35
Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved
43
tacrolimusAstellas PharmaApproved
39